Guidance for Industry on Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals; Availability
Health and Human Services Department, Food and Drug Administration
What is this?
This is a regulatory record from Health and Human Services Department, Food and Drug Administration — a rule, proposed rule, or notice. Regulations carry the force of law once final, and often invite public comment before that point.
Why does it matter?
Regulations are usually what actually binds you, more than statutes are. This is where an agency states the requirement, the effective date, and whether there is still a window to respond.
Key Details
- Posted Date
- NAICS Code
- 621999
- Source
- Federal Register
- Contract Type
- regulation
Description
The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled "Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals." The purpose of this guidance is to provide recommendations to industry for designing nonclinical toxicity studies to determine potential late radiation effects (radiation-induced injuries occurring after a latency period of several months to years) of therapeutic radiopharmaceuticals administered systemically. The purpose of such studies is to help minimize the risk of late-occurring irreversible radiation toxicities in clinical trials of therapeutic radiopharmaceuticals. This guidance finalizes the draft guidance of the same name issued in June 2005.
Frequently Asked Questions
Does this regulation apply to me?+
Follow This Regulation
Follow this regulation in Bureauify to see changes as they are published.
Intelligence
- Win probability analysis
- Competitive landscape
- Incumbent analysis
- Price-to-win estimate
- Similar awards history